International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 335-341 , 1 June 2001

Defining the risk of developing Grade 2 proctitis following 125I prostate brachytherapy using a rectal dose–volume histogram analysis

  • Kurt M Snyder, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • Richard G Stock, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY USA
    • Corresponding Author InformationReprint requests to: Richard G. Stock, M.D., Department of Radiation Oncology, Box 1236, Mount Sinai Hospital, 1184 Fifth Avenue, New York, NY 10029. Tel: (212) 241-7502; Fax: (212) 410-7194
    • ,
  • Suzanne M Hong (M.A.)

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • Yeh Chi Lo, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • Nelson N Stone, M.D.

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, NY USA

,Accepted 20 December 2000.

References 

  1. Stock RG, Stone NN, Tabert A, et al.  A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  2. Beyer DC, Priestley JB. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys. 1997;37:559–563
  3. Blasko JC, Ragde H, Luse RW, et al.  Should brachytherapy be considered a therapeutic option in localized prostate cancer?. Urol Clin North Am. 1996;23:633–650
  4. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 1996;14:449–453
  5. Stock RG, Stone NN, DeWyngaert JK. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer. 1996;77:2386–2392
  6. Stock RG, Stone NN, Wesson MF, et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219–225
  7. Prestidge BR, Bice WS, Kiefer EJ, et al.  Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40:1111–1115
  8. Nag S, Bice W, DeWyngaert K, et al.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221–230
  9. Nath R, Anderson LL, Luxton G, et al.  Dosimetry of interstitial brachytherapy sources (Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43). Med Phys. 1995;22:209–234
  10. Winchester DP, Cox JD. Standards for breast conservation treatment. Ca Center J Clin. 1992;2:134–162
  11. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  12. Cox DR, Oakes D. Analysis of survival data. Chapman and Hall. 1984.
  13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  14. Hanks GE, Schultheiss TE, Hanlon AL, et al.  Optimization of conformal radiation treatment of prostate cancer (Report of a dose escalation study). Int J Radiat Oncol Biol Phys. 1997;37:543–550
  15. Zelefsky MJ, Cowen DM, Fuks Z, et al.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate cancer. Cancer. 1999;85:2460–2468
  16. Skwarchuk MW, Jackson A, Zelefsky MJ, et al.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I) (multivariate analysis and dose-response). Int J Radiat Oncol Biol Phys. 2000;47:103–113
  17. Boersma LJ, van den Brink M, Bruce AM, et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  18. Hartford AC, Niemierko A, Adams JA, et al.  Conformal irradiation of the prostate (Estimating long-term rectal bleeding risk using dose-volume histograms). Int J Radiat Oncol Biol Phys. 1996;36:721–730
  19. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  20. Merrick GS, Butler WM, Dorsey AT, et al.  Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43:1021–1027
  21. Stock RG, Stone NN, Lo YC. Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant. Techniques in Urology. 2000;6:95–98

PII: S0360-3016(01)01442-0

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 335-341 , 1 June 2001

Article Tools

* Image Usage & Resolution